All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Dengue virus (DENV) infection has become more common and virulent over the past half-century. It is in fact, endemic in over 100 countries in Africa, America, and Asia, with 390 million new dengue fever infections \[[@pone.0154760.ref001]\] and approximately 12,000 deaths occurring worldwide every year \[[@pone.0154760.ref002]\].

The WHO classification on severe dengue infection changes overtime. In the 1997 definition, dengue hemorrhagic fever was characterized by having plasma leakage, high fever, hemorrhagic phenomena, hepatomegaly and circulatory failure, whereas dengue shock syndrome was characterized by having narrow pulse pressure (\<20 mmHg (2.7 kPa) \[[@pone.0154760.ref003]\]. Later in 2009, the classification was redefined, in which severe dengue infection was characterized by having plasma leakage, severe bleeding and severe organ impairment \[[@pone.0154760.ref004]\].

1.1 Severity of different serotypes {#sec007}
-----------------------------------

Dengue virus consists of four serotypes with ≥30% difference in their overall amino acid sequences \[[@pone.0154760.ref005]\].

Patients can be infected with more than one serotype of dengue virus in their lifetime. Secondary infection with heterologous serotypes is more severe than primary infection, which may be explained by the antibody-dependent enhancement (ADE) theory. Based on this theory, primary infection leads to the formation of serotype-specific antibodies, which confer long-lasting immunity to the infecting serotype, but short-lasting immunity to other unexposed serotypes. Hence, for secondary infection with different serotypes, the antibodies produced are unable to neutralize the virus, but instead form immune complexes with the virus. These immune complexes have higher affinity towards Fc*γ* receptors on the surfaces of macrophages and other cells, and hence, enhance the entry of the virus into these cells, besides allowing viral replication to occur \[[@pone.0154760.ref006]\]. This theory was reported in a study that involved animal, in which a higher peak viremia was found during secondary infection compared to that during primary infection \[[@pone.0154760.ref007]\].

In addition to the increased severity of secondary infection, certain serotypes were found to cause more severe infections than other serotypes, even during primary infection. For example, Anantapreecha et al \[[@pone.0154760.ref008]\] reported that primary infection with DENV-1 caused severe infections (95% CI, 54.57--67.41) compared to other serotypes (95% CI, 4.58--52.96). This suggests that specific dengue serotypes also play a role in causing severe dengue infections. Moreover, when the immunogenic effects of different serotypes of dengue viruses were compared, it was found that the synthesized NS4A, NS4B, and E peptides of DENV-2 and DENV-3 induced higher total cytokine responses, which included TNF-*α* and IFN-*γ*, compared to other serotypes \[[@pone.0154760.ref009]\]. In contrast, DENV-4 was reported to be less immunogenic \[[@pone.0154760.ref010]\].

Furthermore, since many studies have shown that different serotypes caused different effects upon the severity of dengue infections, this meta-analysis gathered several published evidences from various regions, durations, as well as sample sizes of studies, and synthesized the combined data to evaluate the severity of dengue infection for different dengue serotypes.

Methods {#sec008}
=======

2.1 Literature search {#sec009}
---------------------

A systematic review of dengue hemorrhagic fever, dengue shock syndrome or severe dengue infection was undertaken based on the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements.

### Data sources {#sec010}

A number of relevant articles had been identified via systematic search of MEDLINE from 1946 until present (via Ovid), Non-Indexed Citations (via Ovid), Embase from 1974 up to present (via Ovid), Scopus and PubMed. On top of that, in order to identify comprehensive studies that were not captured by the database searches, the reference lists of the published systematic reviews were manually screened and more articles were successfully retrieved after title and abstract exclusions.

### Search strategies {#sec011}

A search of human studies in inception from February 11, 2014 until July 22, 2015 was performed by using subject headings and free text terms. A search was performed with the keywords "(dengue\* OR dengue virus\*) AND (severe dengue\* OR severity of illness index\* OR severity\* OR DF\* OR DHF\* OR DSS\*) AND (serotypes\* OR serogroup\*)", according to the MESH terms suggested by PubMed and Ovid.

2.2 Inclusion criteria {#sec012}
----------------------

Cross-sectional studies from all publication years concerning dengue patients from all age groups and regions were included. Articles published only in English were evaluated.

2.3 Exclusion criteria {#sec013}
----------------------

The relevance of papers was determined by evaluating their types, objectives and methods. Reviews that did not contain original research data were excluded, so did proceedings that failed to employ the peer-review process. In addition, papers with objectives to study the effects of recombinant proteins from different dengue serotypes on respondents, as well as studies of patients colonized but not infected with dengue virus, were also excluded. Moreover, studies complicated with other diseases were excluded to ensure that dengue virus is the causative agent for all included cases. Finally, papers that did not separate primary infection cases from secondary infection cases were also excluded.

2.4 Data abstraction {#sec014}
--------------------

### Study selection {#sec015}

The titles and the abstracts of the literature search were screened by one reviewer for potentially relevant studies based on the eligibility criteria and they were further double-checked by a second reviewer. After excluding duplicate and apparently irrelevant studies, the full text of the remaining studies were read by two reviewers. The reasons for the exclusion of records were documented during full-text screening. Disagreements between the reviewers were resolved by consensus.

### Data extraction and quality assessment {#sec016}

The following data were extracted independently and in duplicate by two reviewers into a data extraction form: the citation of the study; the number of participants; the characteristics of participants (study population, and age); the study duration; the serotyping method; the WHO classification method; as well as the number of cases that involved dengue hemorrhagic fever, dengue shock syndrome or severe dengue infection caused by different serotypes of the dengue virus. Disagreements were documented and resolved by discussion with a third reviewer; where doubt remained, the authors were contacted for clarification.

2.5 Data analysis {#sec017}
-----------------

Meta-analysis was carried out by using Comprehensive Meta-Analysis (CMA) V3.3.070 software (USA). A fixed effect model and a random effect model were used to calculate the mean effect size in the selected studies without significant heterogeneity (p \> 0.1) and with significant heterogeneity (p \< 0.1), respectively. Besides, in order to identify factors that contributed to the heterogeneity, Begg's funnel plot and Egger linear regression were employed to identify the presence of publication bias, with p \< 0.05 considered as significant for the presence of publication bias. Additionally, sensitivity analysis or study omission analysis was carried out to locate a single study that was responsible for the heterogeneity.

2.6 Definition and Outcomes {#sec018}
---------------------------

Dengue serotypes were confirmed by using either an RT-PCR or an immunofluorescence assay serotyping method. Primary infection is a single infection, whereas secondary infection is an infection that occurs following a primary infection after some time interval. Both serotypes do not exist at the same time. On the other hand, concurrent infection with dual serotypes is defined as an infection with two serotypes of dengue virus that is present simultaneously in a patient. Meanwhile, severe dengue infection is defined as a severe infection, according to the WHO classification from 2009, or dengue hemorrhagic fever or dengue shock syndrome, according to the WHO classification from 1997. There were 2 outcomes that were studied in this meta-analysis. First, the effect size in percentage of severe dengue cases caused by each dengue serotype, subdivided to (1) primary and secondary infection, (2) SEA or non-SEA regions, and (3) 1997 and 2009 WHO dengue classification. Second, the effect size in percentage of secondary dengue infection caused by each dengue serotype subdivided to SEA and non-SEA regions.

Results {#sec019}
=======

3.1 Results of literature search {#sec020}
--------------------------------

The study selection process is depicted in [Fig 1](#pone.0154760.g001){ref-type="fig"}. The sample size, the study period, the population, the age, and the method of serotyping are presented in [Table 1](#pone.0154760.t001){ref-type="table"}. All the selected studies had been retrospective cross-sectional studies. Thirty-one studies were included for review, with 1 study containing data from both Southeast and non-Southeast Asia regions. Moreover, thirty studies portrayed only the severe DHF caused by different dengue serotypes, which was not specific to the severe DHF caused by primary or secondary infection with dengue serotypes. Out of the 30 authors of the papers contacted, 1 of them, Allonso D \[[@pone.0154760.ref011]\], responded to provide unpublished data.

![Flow chart of the study selection process.\
Studies \[[@pone.0154760.ref008],[@pone.0154760.ref011]--[@pone.0154760.ref041]\] were cited in this figure.](pone.0154760.g001){#pone.0154760.g001}

10.1371/journal.pone.0154760.t001

###### Demographic profile.

![](pone.0154760.t001){#pone.0154760.t001g}

  Study                                                            Total number of cases included in this meta-analysis   Population                          Sample collection year   Age (years)     Serotyping                              WHO classification method (year)
  ---------------------------------------------------------------- ------------------------------------------------------ ----------------------------------- ------------------------ --------------- --------------------------------------- -------------------------------------------------
  \[[@pone.0154760.ref013]\]                                       150                                                    Indonesia                           1975--1978               0--14           Hemagglutination-inhibition (HI) test   NA
  \[[@pone.0154760.ref014]\]                                       106                                                    Indonesia                           1995--1996               4--9            RT-PCR, PRNT                            1997
  \[[@pone.0154760.ref015]\]                                       8                                                      Indonesia                           1975--1978               NA              IF, RT-PCR                              NA
  \[[@pone.0154760.ref016]\]                                       165                                                    Thailand                            NA                       \< 14           RT-PCR                                  1997
  \[[@pone.0154760.ref017]\]                                       87                                                     Indonesia                           1998                     1--78           RT-PCR                                  1986
  \[[@pone.0154760.ref018]\]                                       29                                                     Thailand                            1998--2000               \< 12           RT-PCR, PRNT                            1999
  \[[@pone.0154760.ref019]\]                                       257                                                    Thailand                            NA                       3--14           ELISA                                   1997
  \[[@pone.0154760.ref020]\]                                       5616                                                   Thailand                            1973--1999               \< 18           NA                                      1999
  \[[@pone.0154760.ref021]\]                                       104                                                    Thailand                            1998--2000               \< 12           RT-PCR                                  1997
  \[[@pone.0154760.ref008]\]                                       2715                                                   Thailand                            1999--2002               All ages        IF                                      NA
  \[[@pone.0154760.ref022]\]                                       99                                                     Thailand                            2002                     All ages        RT-PCR                                  1997
  \[[@pone.0154760.ref023]\]                                       28                                                     Indonesia                           2004                     1--72           RT-PCR                                  1999
  \[[@pone.0154760.ref024]\]                                       20                                                     Philippines                         2007--2008               1.5--7 months   RT-PCR                                  1997
  \[[@pone.0154760.ref025]\]                                       22                                                     Philippines                         2007--2009               3 months        RT-PCR                                  1997
  \[[@pone.0154760.ref026]\]                                       167                                                    Vietnam                             2006--2008               5--15           RT-PCR                                  2009
  \[[@pone.0154760.ref027]\]                                       76                                                     Vietnam                             2008                     18--31          Real time RT-PCR                        1997
  \[[@pone.0154760.ref028]\]                                       209                                                    Vietnam                             2007--2008               17--27          Real time RT-PCR                        1997
  \[[@pone.0154760.ref041]\][a](#t001fn001){ref-type="table-fn"}   99                                                     Cambodia, Vietnam, French, Brazil   2006--2007               All ages        RT-PCR                                  2009
  \[[@pone.0154760.ref029]\]                                       394                                                    Thailand                            2006--2009               \< 14           RT-PCR                                  1997
  \[[@pone.0154760.ref030]\]                                       133                                                    Thailand                            2006--2008               3--14           RT-PCR                                  1997
  \[[@pone.0154760.ref031]\]                                       64                                                     Philippines                         2005--2006               7--22           RT-PCR                                  1997
  \[[@pone.0154760.ref032]\]                                       134                                                    Thailand                            1994--2002               All ages        RT-PCR                                  1997, 2009
  \[[@pone.0154760.ref033]\]                                       451                                                    Singapore                           2005--2011               18--87          RT-PCR                                  1997, 2009
  \[[@pone.0154760.ref034]\]                                       40                                                     Peru                                2000--2001               NA              RT-PCR                                  1997
  \[[@pone.0154760.ref042]\]                                       3926                                                   Chile, Cuba                         1981, 1997               All ages        PRNT                                    NA
  \[[@pone.0154760.ref035]\]                                       4                                                      Cuba                                2001--2002               NA              RT-PCR, PRNT,                           1994 PAHO[^c^](#t001fn003){ref-type="table-fn"}
  \[[@pone.0154760.ref043]\]                                       89                                                     Santander, Colombia                 1998--2004               NA              IF                                      1980
  \[[@pone.0154760.ref036]\]                                       21                                                     France                              NA                       \> 15           RT-PCR                                  1997
  \[[@pone.0154760.ref037]\]                                       225                                                    Mexico                              2009                     NA              RT-PCR                                  1997
  \[[@pone.0154760.ref011]\][b](#t001fn002){ref-type="table-fn"}   45                                                     Brazil                              NA                       All ages        RT-PCR                                  2009
  \[[@pone.0154760.ref038]\]                                       258                                                    Brazil                              2011                     17--64          RT-PCR                                  2012

^a^ represents paper that contains respondents from both Southeast Asia and non-Southeast Asia (Latin America (Brazil, France)) regions

^b^ represents unpublished data

^c^ represents Pan American Health Organization

NA represents not available

3.2 The relationship between dengue serotypes and disease severity {#sec021}
------------------------------------------------------------------

The effect size of the percentage of severe dengue infections is shown in [Fig 2](#pone.0154760.g002){ref-type="fig"}. No meta-analysis was performed for primary DENV-1, secondary DENV-1 and secondary DENV-4 infections in non-SEA regions as it required more than one study. DENV-4 displayed the lowest total number of cases in both SEA and non-SEA regions (8.08% and 1.07%) compared to other serotypes. Hence, sensitivity analysis was carried out by omitting each individual study to observe its impact upon the quality and the consistency of the results. The results suggested that the study conducted by Nisalak et al \[[@pone.0154760.ref020]\] was reported to affect the heterogeneity of primary DENV-3 infection in the SEA region, while studies carried out by Guzman et al and Ocazionez et al \[[@pone.0154760.ref042],[@pone.0154760.ref043]\] were reported to affect the heterogeneity of secondary DENV-3 infection in non-SEA regions. The heterogeneity did not remain significant after the studies were excluded. The remaining study groups contained no single study that significantly affected the effect size and quality.

![Pooled effect size of the relationship between dengue serotypes and percentage of severe cases.\
The data are arranged in a descending order based on the percentage of severe cases of dengue serotypes. The data are separated by primary and secondary infections, as well as SEA and non-SEA regions, regardless of the WHO classification.](pone.0154760.g002){#pone.0154760.g002}

Furthermore, the analysis ([Fig 2](#pone.0154760.g002){ref-type="fig"}) showed that secondary infection caused a greater percentage of severe infections than primary infection. When the data from all dengue serotypes were clustered into primary, secondary, and concurrent infections and were compared, concurrent infection was found to have higher percentage of severe cases than secondary infection, followed by primary infection. For primary infection, DENV-3 from the SEA region resulted in the highest percentage of severe infections, whereas DENV-2 and DENV-3 from non-SEA regions, as well as DENV-2, DENV-3 and DENV-4 from the SEA region, resulted in greater percentages of severe infections for secondary infection.

When the severity of dengue infections from the SEA region was compared with that of non-SEA regions (Peru, Cuba, France, Colombia, and Brazil), except secondary infections by DENV-2 and DENV-3; all primary and secondary dengue infections had lower percentage of severe cases in non-SEA regions than in the SEA region.

Moreover, DENV-2 and DENV-4 from the SEA region (95% CI, 14.21--14.54), as well as DENV-2 and DENV-3 from non-SEA regions (95% CI, 32.32--35.89), showed a greater difference in the percentage of severe dengue infections between primary and secondary infections compared to other serotypes.

In addition, the effect size of the percentages of DHF, DSS and severe dengue infections is shown in [Fig 3](#pone.0154760.g003){ref-type="fig"}. According to 1997 WHO classification, DENV-3 and DENV-4 were found to result in higher percentage of DHF, whereas DENV-2 and DENV-4 had higher percentage of DSS, compared to other serotypes. According to 2009 WHO classification, DENV-2 from non-SEA regions were found to result in higher percentage of severe dengue infections than other serotypes.

![Pooled effect size of the relationship between dengue serotypes and percentage of DHF, DSS, as well as severe dengue infections.\
The data are arranged in a descending order based on the percentages of DHF, DSS and severe dengue infections. The data are separated by 1997 and 2009 WHO dengue classifications.](pone.0154760.g003){#pone.0154760.g003}

3.3 The relationship between dengue serotypes and secondary infection {#sec022}
---------------------------------------------------------------------

The effect size of the percentage of secondary infection is shown in [Fig 4](#pone.0154760.g004){ref-type="fig"}. DENV-2 and DENV-4 from the SEA region were found to result in higher percentages for secondary infection than other serotypes (95% CI, 72.01--96.32, 9--12 studies, n = 671--2863, I^2^ = 25.01--96.75%). Moreover, the percentage of secondary infection in the SEA region had been found to be higher than that of non-SEA regions. Moreover, results derived from the sensitivity analysis suggested that a study conducted by Dussart et al \[[@pone.0154760.ref041]\] was reported to affect the heterogeneity of DENV-2 infections in SEA regions and DENV-3 infections in non-SEA regions, while a study carried out by Libraty et al \[[@pone.0154760.ref024]\] was reported to affect the heterogeneity of DENV-3 infections in the SEA region. The heterogeneity did not remain significant after these studies were excluded. The remaining study groups contained no single study that significantly affected the effect size and quality.

![Pooled effect size of the relationship between dengue serotypes and secondary infection.\
The data are separated by SEA and non-SEA regions.](pone.0154760.g004){#pone.0154760.g004}

3.4 Results of publication bias assessment {#sec023}
------------------------------------------

When analyzing all 29 studies that examined the association between dengue serotypes and severity, publication bias was detected by using Egger's test (p = 0.000 (\<0.05)), but not detected by using Begg's test (p = 0.8219 (\>0.05)). Besides, for all 18 studies that examined the association of secondary infection, publication bias was detected by using Egger's test (p = 0.007 (\<0.05)), but not detected by using Begg's test (p = 0.211 (\> 0.05)) ([Fig 5](#pone.0154760.g005){ref-type="fig"}).

![Funnel plot of the percentages of severe infections against standard error and funnel plot of the percentages of secondary infection against standard error.\
The percentages of severe infections are displayed on a logarithmic scale. The shapes of both the funnel plots revealed obvious asymmetry.](pone.0154760.g005){#pone.0154760.g005}

Discussion {#sec024}
==========

Previous meta-analyses have addressed the epitope characteristics \[[@pone.0154760.ref039]\] and the host metabolism of dengue virus \[[@pone.0154760.ref040]\]:- the association between clinical signs \[[@pone.0154760.ref044]\] or temperature change \[[@pone.0154760.ref045]\] and the risk of dengue infection:- as well as current treatments for dengue infection such as the tetravalent vaccine \[[@pone.0154760.ref046]\], steroids \[[@pone.0154760.ref047]\] and supportive treatments such as fluid bolus \[[@pone.0154760.ref048]\] or vector control measures \[[@pone.0154760.ref049],[@pone.0154760.ref050]\]. Nonetheless, this meta-analysis compared the percentage of severe cases of different serotypes of dengue virus in primary and secondary infections. Data from previous studies were collected and combined to achieve a sufficient sample size from both primary and secondary infections by each dengue serotype.

4.1 The association between dengue serotypes and severity {#sec025}
---------------------------------------------------------

Secondary infection by each serotype showed greater percentage of severe cases than the respective primary infection ([Fig 2](#pone.0154760.g002){ref-type="fig"}). This strengthens the evidence that antibody-dependent enhancement occurs during secondary infection, which causes more severe infections.

Meanwhile, concurrent infection with dual serotypes is defined as a simultaneous infection with two serotypes of the dengue virus. The results showed that concurrent infections had greater percentage of severe cases than secondary infections and primary infections ([Fig 2](#pone.0154760.g002){ref-type="fig"}), although the difference was small (about 5%). Moreover, Guzman et al and Anderson et al \[[@pone.0154760.ref042],[@pone.0154760.ref051]\] discovered that the longer the interval between the primary and secondary infections, the greater the risk of DHF. Hence, this finding suggests that concurrent infection with multiple serotypes, which represents zero time interval between primary and secondary infections, may present greater severity than both primary and secondary infections. However, as this study only managed to obtain two concurrent infections reported with the percentage of severe cases from SEA regions, the sample size needs to be increased in the future before any conclusion can be made.

According to the 1997 WHO classification, percentage of severe cases of two serotypes were found to be 8--10% higher than other serotypes, whereas according to the 2009 WHO classification, percentage of severe cases of one serotype (DENV-2 from non-SEA regions) was found to be 30% higher than other serotypes. This suggests that 2009 WHO dengue classification showed clearer difference in association of dengue serotypes to the percentage of severe cases. Besides, it was further reported that the 2009 WHO dengue classification is better at representing levels of disease severity \[[@pone.0154760.ref052]\]. This finding also suggests that the use of different dengue classifications affects the clinical prediction of severity caused by each serotype.

4.2 The association between dengue serotypes and secondary infections {#sec026}
---------------------------------------------------------------------

The SEA region depicted a higher percentage of secondary dengue infection than non-SEA regions ([Fig 4](#pone.0154760.g004){ref-type="fig"}), particularly DENV-2 and DENV-4 infections. This finding may be due to the presence of different genotypes in these regions. In particular, the DENV-2 American and Asian/American genotypes have been commonly reported in non-SEA regions \[[@pone.0154760.ref053]--[@pone.0154760.ref055]\], while the DENV-2 Asian I, II, cosmopolitan and American Asian genotypes have been commonly reported in the SEA region \[[@pone.0154760.ref053],[@pone.0154760.ref056]--[@pone.0154760.ref058]\]. The DENV-2 American genotype is less virulent during secondary infection \[[@pone.0154760.ref059]\], and may cause patients to not present clinically, therefore lowering the number of secondary cases recorded. Moreover, the DENV-2 Asian genotype was found to be more associated with secondary infection compared to the DENV-2 American/Asian genotype \[[@pone.0154760.ref056]\].

Nevertheless, studies performed in 2002--2008 in the European Network for Diagnosis of Imported Viral Diseases (ENIVD) showed that the presence of the dengue virus 2 Asian I, II and cosmopolitan genotypes, as well as all dengue virus 4 genotypes (I, II, III, IV and cosmopolitan) among travelers from SEA to Europe. Besides, spreading of the Asian genotypes has been reported in a few other studies in countries in South America (Colombia, Brazil, and Venezuela) \[[@pone.0154760.ref034],[@pone.0154760.ref043]\].

In addition, a higher percentage of secondary infection may also be due to the higher prevalence of dengue outbreaks in the SEA region than non-SEA regions (South America and Europe), which has caused many patients to have a history of past infections. Although there was no significant difference between the number of dengue cases per person and the regions (95% CI SEA-0.1; non-SEA-0.3) from 2002--2015, based on the data obtained from previous studies (\[[@pone.0154760.ref060]--[@pone.0154760.ref070]\], data shown [S1 Supporting Information](#pone.0154760.s002){ref-type="supplementary-material"} sheet 4 Supporting Information sheet 4), many more dengue cases remained unreported. Moreover, the SEA region displayed a higher percentage of secondary infection, although the majority of studies included in SEA reflected belong to infants, who were less likely to have a history of past infections ([Table 1](#pone.0154760.t001){ref-type="table"}). This suggests that dengue cases may be more prevalent in the SEA region, as the populations have been proven to experience dengue infection at a young age.

Meanwhile, DENV-4 portrayed the lowest percentage of the sample size among all four serotypes in both SEA and non-SEA regions (8.08% and 1.07%, according to [Fig 2](#pone.0154760.g002){ref-type="fig"}). Genotypes I and II of DENV-4 showed negative correlations with each other, suggesting an internal competition between the genotypes \[[@pone.0154760.ref071]\]. Moreover, another study reported that DENV-4 is transmitted through the *Aedes albopictus* mosquito, a different species from other serotypes (*Aedes aegypti*) that dwells in areas away from the urban areas with lower human population, and hence, causes a lower rate of transmission \[[@pone.0154760.ref072],[@pone.0154760.ref073]\]. The reasons underlying the reduced circulation of DENV-4, in fact, require further investigation.

4.3 Limitations {#sec027}
---------------

Throughout the study, only a small portion of data from non-SEA regions (Cuba, Peru, France, Colombia and Brazil) had been obtained. Many studies were excluded because they did not separate the primary from the secondary cases of dengue infections caused by each dengue serotype. Some studies were excluded because there were no DHF or severe dengue cases recorded. Therefore, this data was removed to avoid problems in computation of the effect size as suggested by Sterne and Bradburn \[[@pone.0154760.ref074]\]. Hence, although the results ([Fig 2](#pone.0154760.g002){ref-type="fig"}) showed that secondary infection by DENV-2 and DENV-3 from non-SEA regions had higher percentage of severe cases than those in the SEA region, this does not imply that dengue infections in non-SEA regions are more severe. Torres and Castro \[[@pone.0154760.ref075]\] showed that only 3.4% of the sample size of 427,627 dengue patients in Latin America suffered from DHF, which is lower than the percentages shown in this study (10.57% and 48.29% in primary and secondary infections of all dengue serotypes, respectively). Use of different WHO classification was also found to affect the association between dengue serotypes and severe cases. More studies are needed in the future before any conclusions can be made. Moreover, publication bias was identified in this study, which suggests that more unpublished data are needed for more robust statistical results. On top of that, sensitivity analysis was performed, and studies that affected the consistency and the quality of the results were identified as they affected the robustness of the statistical results.

Besides, as studies included are retrospective studies, they present with inferior level of evidence compared to prospective studies. Details such as days of admission and age of patients in each dengue serotypes and in primary and secondary infections were only recorded in 6 and 12 studies, respectively, out of 31 studies included in this meta-analysis (data shown in [S1 Supporting Information](#pone.0154760.s002){ref-type="supplementary-material"} document sheet 6). Hence, no meta-regression was performed. Aging was found to be associated with co-morbidities that lead to impairments of kidney, liver and lung \[[@pone.0154760.ref076]--[@pone.0154760.ref078]\], that comprise the 2009 WHO classification definition of severe cases. Late admission of dengue cases and inadequate monitoring in hospital may also enhance severity of infections. These details are crucial as they may become confounding factors for the study of association between dengue serotypes, types of infections and percentage of severe dengue cases. Future studies that consider these confounding factors are needed.

4.4 Conclusion {#sec028}
--------------

As the severity of dengue infection had been found to be affected by the dengue serotypes involved and also the interval between the primary and secondary infections, these factors need to be considered when clinical prediction of the severity of dengue patients is being made. Moreover, as certain serotypes resulted in higher percentage of severe cases, such as secondary infection by SEA DENV-2, DENV-3, DENV-4, and non-SEA DENV-2, DENV-3 or primary infections by DENV-3 from SEA: these serotypes require proper clinical attention.

Moreover, since DENV-4 was found to cause the lowest percentage of the sample size; serotype-specific antiviral treatments may be more focused on the other serotypes, DENV-1, DENV-2 and DENV-3. Besides, as DENV-2 and DENV-4 had been more associated with secondary infection, patients with a history of past dengue infection should take extra precautions during outbreaks of DENV-2 and DENV-4 infections.

Supporting Information {#sec029}
======================
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Sheet 1 Relationship between dengue serotypes and percentage of severe cases Sheet 2 Relationship between dengue serotypes and percentage of DHF, DSS, as well as severe dengue infections Sheet 3 Relationship between dengue serotypes and secondary infection Sheet 4 Dengue cases in SEA and non-SEA regions Sheet 5 Publication bias Sheet 6 Age and days of admissions of patients

(XLSX)

###### 

Click here for additional data file.
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